SG
ARTL icon

StoneX Group’s Artelo Biosciences ARTL Stock Holding History

StoneX Group’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-56
Closed -$4.75K – 367
2022
Q2 		$4.75K Buy
+56
New +$5.51K ﹤0.01% 481

Other funds holding ARTL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

StoneX Group's ARTL Position: Q3 2022 in Review

StoneX Group sold out of Artelo Biosciences (ARTL) in Q3 2022, closing a stake of 56 shares — an estimated $4.75K sold.

StoneX Group first reported a position in ARTL in Q2 2022 and held it in 1 quarter. The position peaked at $4.75K in Q2 2022. 9 funds tracked by Wall St. Rank hold ARTL as of Q3 2022.

  • StoneX Group reported no remaining Artelo Biosciences position as of Q3 2022 after selling out during the quarter.
  • StoneX Group sold 56 Artelo Biosciences shares in Q3 2022, an estimated $4.75K.
  • StoneX Group first reported a position in Artelo Biosciences in Q2 2022 and held it in 1 quarter.
  • StoneX Group's Artelo Biosciences position peaked at $4.75K in Q2 2022.
  • 9 funds tracked by Wall St. Rank held Artelo Biosciences as of Q3 2022.

Based on StoneX Group's 13F filing for Q3 2022, filed 8 Nov 2022.